Acoustic Microfluidics Ushers in Precise Circulating Tumour Cell Separation

A novel acoustofluidic platform has emerged, aiming to enhance early cancer detection by isolating circulating tumour cells quickly and efficiently.

• New AI-integrated acoustofluidic system demonstrates 100% circulating tumour cell recovery at optimum conditions
• Dual pressure acoustic fields target red blood cell separation with precision
• Lower energy usage and potential for streamlined laboratory-on-chip device design

Cancer remains a leading cause of death worldwide, with an estimated 10 million fatalities in 2020 alone, according to the World Health Organization. Early detection is widely recognised as a key factor in improving survival rates, yet existing methods for identifying abnormal diseased cell growth can be limited by time and technical complexity. Researchers have increasingly looked towards microfluidics – in particular, the use of surface acoustic waves – to refine the process of isolating rare circulating tumour cells (CTCs) that can help inform timely diagnoses.

Advanced Acoustofluidics

A new system proposed by two researchers at the K. N. Toosi University of Technology in Tehran, Iran, builds upon recent developments in microfluidics by combining standing surface acoustic waves with advanced computational and artificial intelligence methods. “We combined machine learning algorithms with data-driven modelling and computational data to fine-tune a system for optimal recovery rates and cell separation rates,” said researcher Naser Naserifar. “Our system achieves 100% recovery at optimal conditions, with significant reductions in energy consumption through precise control of acoustic pressures and flow rates.”

By utilising acoustofluidics, the design integrates two overlapping pressure fields within a microchannel, effectively doubling the forces acting on target CTCs. These fields are strategically positioned on a lithium niobate substrate to generate predictable pressure gradients, guiding cells into defined trajectories and separating them from red blood cells. The platform’s lab-on-chip design promises biocompatibility, efficient use of sample volumes, and better alignment with existing clinical workflows. In doing so, it addresses one of the persistent difficulties in cancer research – the need for a method that requires minimal preparation, yet offers high accuracy in isolating low-abundance targets.

Future Potential

The system’s creators highlight its ability to reduce costs and energy demands without compromising on separation efficiency. Such advantages could be pivotal for laboratories seeking more streamlined ways to isolate CTCs and potentially identify cancers in their earliest stages. “We have produced an advanced, lab-on-chip platform that enables real-time, energy-efficient, and highly accurate cell separation,” said researcher Afshin Kouhkord. “The technology promises to improve CTC separation efficiency and open new possibilities for earlier and more effective cancer diagnosis. It also paves the way for microengineering and applied AI in personalised medicine and cancer diagnostics.”

With minimal disruption to cell viability, acoustofluidic approaches are poised to support a wide range of biomedical applications. By leveraging computational modelling and data-driven algorithms, this new platform stands out among other microfluidic techniques, offering a precision-based solution that can adapt to different sample conditions. It is expected that further development of this technology will enable faster turnaround times in both research and clinical settings, while opening doors to more refined diagnostics and potential personalised treatment paths.

As microfluidics continues to grow in prominence, research into acoustofluidic cell isolation could transform cancer screening protocols. This latest work underlines the importance of interdisciplinary collaboration, blending expertise in physics, engineering, artificial intelligence, and biomedical research. In the long term, refining these techniques may help clinicians worldwide to diagnose cancer earlier and tailor treatments more effectively, ultimately reducing the global burden of this multifaceted disease.